Search Results - Andreas Erhardt

  • Showing 1 - 15 results of 15
Refine Results
  1. 1
    Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

    Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D by Andreas Erhardt

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Hepatitis C Virus Core Protein Induces Cell Proliferation and Activates ERK, JNK, and p38 MAP Kinases Together with the MAP Kinase Phosphatase MKP-1 in a HepG2 Tet-Off Cell Line

    Hepatitis C Virus Core Protein Induces Cell Proliferation and Activates ERK, JNK, and p38 MAP Kinases Together with the MAP Kinase Phosphatase MKP-1 in a HepG2 Tet-Off Cell Line by Andreas Erhardt, Mohamed Hassan, Tobias Heintges, Dieter Häussinger

    Published 2002
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage

    Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage by Abdurrahman Sagir, Andreas Erhardt, Marcus Schmitt, Dieter Häussinger

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Plasma levels of vitamin e and carotenoids are decreased in patients with nonalcoholic steatohepatitis (nash)

    Plasma levels of vitamin e and carotenoids are decreased in patients with nonalcoholic steatohepatitis (nash) by Andreas Erhardt, Wilhelm Stahl, Helmut Sies, Flavio Lirussi, Allan Donner, Dieter Häussinger

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B

    Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B by Andreas Erhardt, Ulf Reineke, D. Blondin, Wolfram H. Gerlich, Ortwin Adams, Tobias Heintges, Claus Niederau, Dieter Häussinger

    Published 2000
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis

    HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis by Andreas Erhardt, Andrea Maschner-Olberg, Claudia Mellenthin, Günther Kappert, Ortwin Adams, Andreas Donner, R. Willers, Claus Niederau, Dieter Häussinger

    Published 2003
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Prognosis of chronic hepatitis c: Results of a large, prospective cohort study

    Prognosis of chronic hepatitis c: Results of a large, prospective cohort study by Claus Niederau, Stefan Lange, Tobias Heintges, Andreas Erhardt, M. Buschkamp, D. Hürter, Marek Nawrocki, Lothar Kruska, Frank Hensel, W. Petry, Dieter Häussinger

    Published 1998
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase

    Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase by Erwin Daniel Brenndörfer, Juliane Karthe, Lars Frelin, Patricia Cebula, Andreas Erhardt, Jan Schulte Am Esch, Hartmut Hengel, Ralf Bartenschlager, Matti Sällberg, Dieter Häussinger, Johannes G. Bode

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Development and evaluation of a baseline‐event‐anticipation score for hepatitis delta

    Development and evaluation of a baseline‐event‐anticipation score for hepatitis delta by B. Calle Serrano, Anika Großhennig, María Homs, Benjamin Heidrich, Andreas Erhardt, Katja Deterding, Jerzy Jaroszewicz, Birgit Bremer, Armin Koch, Markus Cornberg, Michael P. Manns, Marı́a Buti, Heiner Wedemeyer

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients

    Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients by Holger Hinrichsen, Yves Benhamou, Heiner Wedemeyer, Markus Reiser, Roel Sentjens, José Luís Calleja, Xavier Forns, Andreas Erhardt, Jens Crönlein, Ricardo L. Chaves, Chan‐Loi Yong, Gerhard Nehmiz, Gerhard Steinmann

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta

    Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta by Heiner Wedemeyer, Cihan Yurdaydın, George Ν. Dalekos, Andreas Erhardt, Yılmaz Çakaloğlu, Halil Değertekin, Selım Gürel, Stefan Zeuzem, Kalliopi Zachou, Hakan Bozkaya, Armin Koch, C.‐Thomas Bock, Hans Peter Dienes, Michael P. Manns

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion

    Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion by Markus Cornberg, Ulrike Protzer, J. Petersen, Heiner Wedemeyer, Thomas Berg, Wolfgang Jilg, Andreas Erhardt, Stéfan Wirth, Christoph Sarrazin, Matthias Dollinger, Peter Schirmacher, Katarina Dathe, I. Kopp, Stefan Zeuzem, Wolfram H. Gerlich, Michael P. Manns

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta

    Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta by Benjamin Heidrich, Cihan Yurdaydın, Gökhan Kabaçam, Boris A. Ratsch, Kalliopi Zachou, Birgit Bremer, George Ν. Dalekos, Andreas Erhardt, Fehmı Tabak, Kendal Yalçın, Selım Gürel, Stefan Zeuzem, Markus Cornberg, C.‐Thomas Bock, Michael P. Manns, Heiner Wedemeyer

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment

    Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment by Andreas Erhardt, Katja Deterding, Yves Benhamou, Markus Reiser, Xavier Forns, Stanislas Pol, José Luís Calleja, Susanne Ross, Hans Christian Spangenberg, Javier García‐Samaniego, Michael Fuchs, Jaime Enríquez, Johannes Wiegand, Jerry O. Stern, K. Wu, George Kukolj, Martin Marquis, Pierre L. Beaulieu, Gerhard Nehmiz, Jürgen Steffgen

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta

    Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta by A. Wranke, Benjamin Heidrich, Stefanie Ernst, Beatriz Calle Serrano, Florin Alexandru Căruntu, Manuela Curescu, Kendal Yalçın, Selım Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George Papatheodoridis, Birgit Bremer, Judith Stift, Jan Grabowski, J. Kirschner, Kerstin Port, Markus Cornberg, Christine S. Falk, Hans‐Peter Dienes, Svenja Hardtke, Michael P. Manns, Cihan Yurdaydın, Heiner Wedemeyer

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: